ClinicalTrials.gg

Program

giredestrant

Also written as “Giredestrant”, “GDC-9545” and “[14C]-GDC-9545”.

Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms · Ovarian Neoplasms, led by Hoffmann-La Roche.

Furthest: phase 3, since Sep 8, 202017 company-led studies, 12 open or runningNext primary completion: Jul 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche1712 open or runningphase 3since Sep 8, 2020Nov 1, 2017Jul 31, 2027phase 1 · NCT03332797
  • Named in Hoffmann-La Roche’s own pipeline as RG6171 giredestrant, phase 4, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 1, 2017.

  1. Sep 8, 2020Phase 3 study in Breast NeoplasmsNCT04546009 · 992 enrolled · United States, Argentina, Australia and more
  2. Sep 30, 2020Phase 2 study in Breast NeoplasmsNCT04576455 · 303 enrolled · United States, Argentina, Australia and more
  3. Dec 17, 2020Phase 1 study in Healthy VolunteersNCT04680273 · 16 enrolled · United Kingdom
  4. Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
  5. Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
  6. Jul 5, 2021Phase 3 study in Breast NeoplasmsNCT04961996 · 4,170 enrolled · United States, Argentina, Australia and more
  7. Mar 23, 20222 phase 3 studies in Breast NeoplasmsNCT05306340, NCT05296798
  8. Nov 21, 2022Phase 2 study in Endometrial NeoplasmsNCT05634499 · 33 enrolled · United States, Canada, Italy and more
  9. Sep 26, 2023Phase 3 study in Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06065748 · 1,050 enrolled · United States, Argentina, Australia and more
  10. Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
  11. Apr 15, 2026Phase 3 study in Breast NeoplasmsNCT07541079 · 300 planned · United States
  12. Sep 15, 2026Phase 3 study in Breast NeoplasmsNCT07827573 · 1,500 planned · United States, Canada
  13. Sep 29, 2026Primary completion moved from 2027-10-31 to 2027-12-31Date moved laterphase 3 · +2 months · NCT05296798
  14. Oct 2, 2026Primary completion moved from 2027-12-31 to 2028-06-15Date moved laterphase 3 · +5 months · NCT05296798

Ahead

  1. Jul 31, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07054190
  2. Jul 31, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT03332797
  3. Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04931342
  4. Apr 20, 2028Primary completion: phase 3 study in Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06065748

TargetBeta

“An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevent…”NCIt, read by Claude
“An orally available selective estrogen receptor degrader/downregulator (SERD), ”NCIt, by rule
“Estrogen receptor alpha degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07827573Breast Neoplasms · United States, Canada3RecruitingNov 30, 20281,500
NCT07541079Breast Neoplasms · United States3RecruitingJun 30, 2032300
NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more2RecruitingJul 31, 2027120
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer · United States, Argentina, Australia and more3Active, not recruitingApr 20, 20281,050
NCT05634499Endometrial Neoplasms · United States, Canada, Italy and more2CompletedAug 25, 202633
NCT05306340Breast Neoplasms · United States, Argentina, Germany and more3Active, not recruitingJul 16, 2025373
NCT05296798Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingJun 15, 2028922
NCT04961996Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAug 8, 20254,170
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingFeb 28, 2028176
NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more2RecruitingMay 30, 2029316
NCT04680273Healthy Volunteers · United Kingdom1CompletedApr 12, 202116
NCT04576455Breast Neoplasms · United States, Argentina, Australia and more2Active, not recruitingFeb 18, 2022303
NCT04546009Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingJan 30, 2026992
NCT04436744Breast Neoplasms · United States, Australia, Brazil and more2CompletedJul 6, 2021221
NCT04274075Healthy Volunteers · United States1CompletedApr 16, 202018
NCT03916744Breast Neoplasms · United States, Australia, Belgium and more1CompletedMay 25, 202175
NCT03332797Breast Neoplasms · United States, Australia, South Korea and more1Active, not recruitingJul 31, 2027181

How it is read

Names in the registry

  • “Giredestrant”, 14 entries
  • “GDC-9545”, 1 entry
  • “[14C]-GDC-9545”, 1 entry
  • “GDC-9545 Solution for Infusion”, 1 entry
  • “GDC-9545/F12 Capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.